All articles by Aidan McNamee

Aidan joined Pharmaceutical Technology as a trainee reporter in 2023. With a background in data journalism, he has worked in consumer media covering a wide range of topics, and has a particular interest in big data, AI and the metaverse. Previously, Aidan worked with the Reach Data Unit as part of the Google News Initiative fellowship.

Aidan McNamee

Eikon Therapeutics bag $106m to fund eager acquisitions

Funding will be used to support the company’s platform based on Nobel Prize winning research.

Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar

Coherus Biosciences’ biosimilar Yusimry will have a significantly lower cost than AbbVie’s Humira.

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

The anti-CD 40L antibody was associated with a a significant reduction in lesions in the Phase II study.

AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer

The approval is for the use of Lynparza in combination with Zytiga and prednisone, standard drugs for mCRPC

SNIPR targets antibiotic resistance with CRISPR-based gene therapy trial

The company announced early safety data with a gene therapy against antibiotic-resistant bacteria.

After US approval, Amylyx faces regulatory hurdle in Europe for ALS treatment

Relyvrio is once again at the heart of another debate over ALS trial endpoints; this time in Europe.

Early signals suggest oral SERD’s potential for more breast cancer patients

The company is presenting exploratory results at ASCO, which demonstrates new use cases for the oral SERD.

AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery

The startup will utilise cutting edge methods to accelerate drug discovery research.

Touchlight boosts DNA manufacturing capacity with latest expansion

The larger facility is expected to help Touchlight supply plasmid DNA to meet the demand for cell and gene therapy production.